Alnylam to Webcast Presentation at Canaccord Genuity 43rd Annual Growth Conference

Rhea-AI Summary

ALNY - Alnylam Pharmaceuticals to Present Company Overview at Canaccord Genuity 43rd Annual Growth Conference on August 10, 2023

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Canaccord Genuity 43^rd Annual Growth Conference on Thursday, August 10, 2023 at 10:30 am ET at the InterContinental Hotel in Boston.

A live audio webcast of the presentation will be available on the Investors section of the Company’s website at www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after each event.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding in 2002, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam’s commercial RNAi therapeutic products are ONPATTRO^® (patisiran), AMVUTTRA^® (vutrisiran), GIVLAARI^® (givosiran), OXLUMO^® (lumasiran), and Leqvio^® (inclisiran), which is being developed and commercialized by Alnylam’s partner, Novartis. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its “Alnylam P⁵x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on X (formerly Twitter) at @Alnylam, or on LinkedIn, Facebook, or Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230802309582/en/

Alnylam Pharmaceuticals, Inc.

Christine Regan Lindenboom

(Investors and Media)

617-682-4340

Josh Brodsky

(Investors)

617-551-8276

Source: Alnylam Pharmaceuticals, Inc.

What is the event Alnylam Pharmaceuticals will be presenting at?

Alnylam Pharmaceuticals will be presenting a company overview at the Canaccord Genuity 43rd Annual Growth Conference on August 10, 2023.

Where will the presentation take place?

The presentation will take place at the InterContinental Hotel in Boston, with a live audio webcast available on the Investors section of the Company’s website.

How can I access the live webcast?

The live audio webcast of the presentation will be available on the Investors section of the Company’s website at www.alnylam.com/events.

Will there be a replay available?

Yes, a replay will be available on the Alnylam website within 48 hours after the event.